Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
AuthorsBrooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA,
JournalCancer
PubMed ID21523723
'Treatment options for patients with advanced head and neck squamous cell carcinoma (HNSCC) are scarce. This phase 2 study was conducted to evaluate the safety, tolerability, pharmacokinetics, and efficacy of dasatinib in this setting. Patients with recurrent and/or metastatic HNSCC after platinum-based therapy were treated with dasatinib either orally or ... More
Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury.
AuthorsKwon BK, Stammers AM, Belanger LM, Bernardo A, Chan D, Bishop CM, Slobogean GP, Zhang H, Umedaly H, Giffin M, Street J, Boyd MC, Paquette SJ, Fisher CG, Dvorak MF,
JournalJ Neurotrauma
PubMed ID20038240
There is an urgent need for both the scientific development and clinical validation of novel therapies for acute spinal cord injury (SCI). The scientific development of novel therapies would be facilitated by a better understanding of the acute pathophysiology of human SCI. Clinical validation of such therapies would be facilitated ... More